Xenon Pharmaceuticals (NASDAQ:XENE) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research began coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a research note published on Monday, MarketBeat.com reports. The firm issued an outperform rating and a $60.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on XENE. Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Wells Fargo & Company lifted their price objective on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an “overweight” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. increased their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Cantor Fitzgerald restated an “overweight” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $55.17.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ:XENE opened at $44.58 on Monday. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of -11.46 and a beta of 0.96. Xenon Pharmaceuticals has a 1-year low of $26.74 and a 1-year high of $46.60. The company’s fifty day moving average is $42.48 and its two-hundred day moving average is $40.92.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the transaction, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This represents a 86.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 65,302 shares of company stock valued at $2,924,128. Insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in XENE. Corient Private Wealth LLC bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $1,125,000. Mackenzie Financial Corp acquired a new position in Xenon Pharmaceuticals in the 4th quarter valued at approximately $210,000. ADAR1 Capital Management LLC lifted its holdings in Xenon Pharmaceuticals by 7.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock worth $9,142,000 after buying an additional 14,871 shares during the period. XTX Topco Ltd acquired a new stake in Xenon Pharmaceuticals during the 4th quarter valued at approximately $964,000. Finally, Virtus Investment Advisers LLC lifted its holdings in Xenon Pharmaceuticals by 74.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 2,568 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.